SBIR/STTR Research Award

High-Copy Number Cloning of Toxic Genes

Award identifier 6cfce574634fbb675972841c542024730ef091253c6759d920f4012ddc9e2ff6Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$118,223

Program and phase

SBIR · Phase I

Award year

2005

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
BLUE HERON BIOTECHNOLOGY, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2005-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): A small but significant fraction of recombinant clones are unstable in E. coli and thus difficult to clone and manipulate using the standard techniques of molecular biology. Many of these cDNAs and genes encode proteins that are toxic to the bacteria even when expressed at very low levels. For instance, only a few molecules of specific proteases, RNAses or ion channels can severely disrupt the growth or survival of a bacterial cell. This proposal is focused on developing a set of new molecular tools to block the functional expression of toxic proteins and allow the propagation of DNA sequences encoding these genes using standard, high-copy plasmid vectors. These tools will function by reducing the expression and activity of toxic gene products. They could replace requirements for special growth conditions, low-copy vectors, special bacterial strains and ether non-standard techniques, and thus simplify the manipulation of toxic genes. The primary objective of this research is to allow simple and efficient cloning and manipulation of genes and cDNAs that are currentlydifficult to grow in E. coli. Blue Heron Biotechnology is a gene synthesis company. If successful, the new technologies will be commercialized in two ways, 1) by improving the reliability of the company s current gene synthesis business, and 2) by selling kits or services using these new technologies

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.